US 11,865,129 B2
Application of anemoside B4 in preparation of a drug for treatment or prevention of psoriasis
Hongwei Gao, Suzhou (CN); Shilin Yang, Suzhou (CN); Renyikun Yuan, Suzhou (CN); and Xiaoran Li, Suzhou (CN)
Assigned to GUANGXI XINHAI PHARMACEUTICAL TECHNOLOGY CO., LTD., Liuzhou (CN)
Filed by GUANGXI XINHAI PHARMACEUTICAL TECHNOLOGY CO., LTD., Liuzhou (CN)
Filed on Jun. 2, 2022, as Appl. No. 17/805,217.
Claims priority of application No. 202111601109.7 (CN), filed on Dec. 24, 2021.
Prior Publication US 2023/0201230 A1, Jun. 29, 2023
Int. Cl. A61K 31/704 (2006.01); A61P 17/06 (2006.01); A61K 9/00 (2006.01)
CPC A61K 31/704 (2013.01) [A61K 9/0014 (2013.01); A61P 17/06 (2018.01)] 6 Claims
 
1. A method for treating psoriasis comprising a step of administering a therapeutic effective dosage of anemoside B4 with a structural formula (I) to a subject in need; wherein the therapeutic effective dosage of the anemoside B4 is 1-20 mg/kg per day;

OG Complex Work Unit Chemistry